38.54M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Poxel S. A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan.

Similar securities

Based on sector and market capitalization

Report issue